Wayne State University and Oakwood Partner in New Device to Combat Congestive Hea...(iently. The condition is characterized b...),Health

Date:4/7/2008

iently. The condition is characterized by a compromising of the heart's ability to squeeze, and often by seepage of fluid into the lungs, feet, legs or abdominal cavity. The heart muscle's inability to keep up with the body's demands can cause the heart to enlarge, increasing stress on the heart wall. The HeartNet counteracts the condition through gentle pressure on the heart.

The American Heart Association and the Heart Failure Society of America estimate that more than 5 million Americans have been diagnosed with heart failure and that 500,000 more diagnoses are made each year. Heart failure is the leading cause of hospital admissions in the U.S. Only about half of Americans diagnosed with heart failure will survive more than five years. Each year, more than 300,000 people die from the condition.

"The potential effects of this study and the HeartNet hold tremendous promise," said Robert M. Mentzer Jr., M.D., dean of the Wayne State University School of Medicine and senior advisor to the president for medical affairs. Dr. Mentzer, a nationally recognized cardiothoracic surgeon who has performed numerous heart transplants, serves as co-principal investigator of the clinical research study, along with Salik A. Jahania, M.D., a cardiothoracic surgeon with the Wayne State University Physician Group and Oakwood Healthcare System. Dr. Jahania performed the procedure.

"More research is needed, but the HeartNet appears to offer the possibility of not only halting but potentially reversing congestive heart failure," Dr. Mentzer said. "The implant could reduce the need for heart transplants among some patients."

Along with Drs. Mentzer and Jahania, Peter Vitkevicius, M.D., and Arthur Riba, M.D., were instrumental in identifying and evaluating patients for the purposes of the study.

The investigational HeartNet is a mesh constructed of nitinol, a nickel-titanium alloy. Because the device conforms to the shape of the heart -- expand
'/>"/>

SOURCE Oakwood Healthcare System; Wayne State University Schoolof Medicine Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
4. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
8. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
9. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
10. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
11. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds